Real-world efficacy and safety outcomes for patients with relapsed or refractory (R/R) aggressive B-cell non-Hodgkin's lymphoma (aBNHL) treated with commercial tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry

Updated real-world data presented during the 2021 ASH Annual Meeting demonstrated that the safety and efficacy of CAR T-cell therapy tisagenlecleucel for patients with relapsed/refractory DLBCL or high-grade B-cell lymphoma was consistent with that of the phase 2 JULIET trial. Efficacy factors included overall response, complete response, and progression-free survival, among others, and adverse events included cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.